The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased GeneDX Holdings securities between April 16, 2025 and May 4, 2026. The complaint alleges the company and its executives made false or misleading statements and failed to disclose issues including the importance of Fabric Genomics, the durability of average reimbursement rates, and the impact on gross margins. On May 4, 2026, after the market closed, GeneDX reported first-quarter financial results that missed expectations for both its exome and genome lines and cut its 2026 revenue guidance from $540-555 million to $475-490 million. The company also disclosed an average reimbursement rate of $3,300, $200 below expectations, and a $31.3 million goodwill impairment charge related to the Fabric Genomics acquisition, which it had purchased for $36.5 million a year earlier. Following this news, GeneDX shares fell over 49%, or $33.42 per share, from the previous close. Investors have until August 3, 2026 to file a lead plaintiff motion.
GeneDx Holdings Corp.Missed Q1 earnings, cut 2026 revenue guidance, and disclosed a goodwill impairment charge, causing a 49% stock drop.
The goodwill impairment charge on Fabric Genomics acquisition indicates the acquisition underperformed, negatively impacting its valuation.